UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G Under the Securities Exchange Act of 1934

VERVE THERAPEUTICS, INC.
(Name of Issuer)
COMMON STOCK, PAR VALUE \$0.001 PER SHARE
(Title of Class of Securities)
92539P101
(CUSIP Number)
JUNE 21, 2024
(Date of event which requires filing of this statement)

	□ Rule 13d-1(b)
	☑ Rule 13d-1(c)
	□ Rule 13d-1(d)
Т	he remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for an

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the notes).

CUSIP No	92539P101	SCHEDULE 13G	Page	2	of [10
N	NAMES OF REPORTING PER	SONS				

_	NAMES OF REPORTING PERSONS							
1	Millennium Management LLC							
	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP							
2	(a) \square	IE BUA	IF A WEWIDER OF A GROUP					
_	(b) \square							
3	SEC USE ONLY							
	CITIZENSHIP OR PLACE	CITIZENSHIP OR PLACE OF ORGANIZATION						
4								
	Delaware							
			SOLE VOTING POWER					
		5						
	AHD (DED OF		-0-					
	NUMBER OF SHARES		SHARED VOTING POWER					
	BENEFICIALLY	6						
	OWNED BY		4,301,005					
	EACH	_	SOLE DISPOSITIVE POWER					
	REPORTING PERSON WITH	7	-0-					
			SHARED DISPOSITIVE POWER					
		8	SHARED DISTOSITIVE TOWER					
			4,301,005					
	AGGREGATE AMOUNT B	ENEFIC	IALLY OWNED BY EACH REPORTING PERSON					
9								
	4,301,005							
	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES							
10								
	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)							
11	PERCENT OF CLASS REP	KESENI	ED BY AMOUNT IN ROW (9)					
11	5.1%							
	TYPE OF REPORTING PER	RSON						
12		I I FE OF REFORTING FERSON						
	00							

CUSIP No. [92539P101	SCHEDULE 13G	Page	3	of	10

1	NAMES OF REPORTING	PERSON	IS .				
-	Millennium Group Management LLC						
2		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) □					
2	(a) \Box (b) \Box						
3	SEC USE ONLY						
4	CITIZENSHIP OR PLACE OF ORGANIZATION						
4	Delaware						
			SOLE VOTING POWER				
		5	-0-				
	NUMBER OF		SHARED VOTING POWER				
	SHARES BENEFICIALLY	6					
	OWNED BY		4,301,005 SOLE DISPOSITIVE POWER				
	EACH REPORTING PERSON WITH	7	SOLE DISPOSITIVE POWER				
			-0-				
		8	SHARED DISPOSITIVE POWER				
			4,301,005				
	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON						
9	4,301,005						
	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES						
10							
	PERCENT OF CLASS REI	PRESEN'	TED BY AMOUNT IN ROW (9)				
11		RESERV	TED BY AMOUNT IN ROW (7)				
	5.1%	n a o					
12	TYPE OF REPORTING PE	RSON					
12	00						

CUSIP No. 92539P101 SCHEDULE 13G Page 4 of	10
--	----

1	NAMES OF REPORTING I Israel A. Englander							
2	(a) □ (b) □	(b) (b)						
3	SEC USE ONLY							
4	CITIZENSHIP OR PLACE OF ORGANIZATION United States							
	NUMBER OF	5	SOLE VOTING POWER -0-					
	NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	6	SHARED VOTING POWER 4,301,005					
		7	SOLE DISPOSITIVE POWER -0-					
		8	SHARED DISPOSITIVE POWER 4,301,005					
9	4,301,005		IALLY OWNED BY EACH REPORTING PERSON					
10	_		E AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES					
11	5.1%	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 5.1%						
12	TYPE OF REPORTING PE	RSON						

CUSIP No	0.	92539P101 SCHEDULE 13G	Page
Item 1.	(a)	Name of Issuer:	
		Verve Therapeutics, Inc.	
	(b)	Address of Issuer's Principal Executive Offices:	
		201 Brookline Avenue, Suite 601 Boston, Massachusetts 02215	
Item 2.	(a) (b) (c)	Address of Principal Business Office:	
		Millennium Management LLC 399 Park Avenue New York, New York 10022 Citizenship: Delaware	
		Millennium Group Management LLC 399 Park Avenue New York, New York 10022 Citizenship: Delaware	
c/o Millennium Ma 399 Park Avenue New York, New Yo		Israel A. Englander c/o Millennium Management LLC 399 Park Avenue New York, New York 10022 Citizenship: United States	
	(d)	Title of Class of Securities:	
		common stock, par value \$0.001 per share ("Common Stock")	
	(e)	CUSIP Number:	
		92539P101	
Item 3. If	this state	ement is filed pursuant to Rule 13d-1(b), or 13d-2(b), check whether the person filing is a:	
(a)		Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);	
(b)		Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);	
(c)		Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);	
(d)		Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80)a-8);
(e)		An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);	

An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

(f)

CUSIP No.		92539P101	SCHEDU	LE 13G	Page	6	of [10	
(g)		A parent holding comp	any or control person in accordance with	\$240.13d-1(b)(1)(ii)(G);					
(h)		A savings association a	savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);						
(i)		A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);							
(j)		Group, in accordance v	ith §240.13d-1(b)(1)(ii)(J).						
Item 4. Owr	ership	!							
Provide th	e follo	wing information regard	ing the aggregate number and percentage	of the class of securities of the issue	er identified i	n Item 1			
(a) Amount	(a) Amount Beneficially Owned:								
See respor	See response to Item 9 on each cover page.								
(l-) D	- C (1								

(b) Percent of Class:

See response to Item 11 on each cover page.

(c) Number of shares as to which such person has:

(i) Sole power to vote or to direct the vote

See response to Item 5 on each cover page.

(ii) Shared power to vote or to direct the vote

See response to Item 6 on each cover page.

(iii) Sole power to dispose or to direct the disposition of

See response to Item 7 on each cover page.

(iv) Shared power to dispose or to direct the disposition of

See response to Item 8 on each cover page.

The securities disclosed herein as potentially beneficially owned by Millennium Management LLC, Millennium Group Management LLC and Mr. Englander are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers that may be controlled by Millennium Group Management LLC (the managing member of Millennium Management LLC) and Mr. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). The foregoing should not be construed in and of itself as an admission by Millennium Management LLC, Millennium Group Management LLC or Mr. Englander as to beneficial ownership of the securities held by such entities.

Item 5. Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following \Box .

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not applicable.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

Not applicable.

Item 8. Identification and Classification of Members of the Group

See Exhibit I.

Item 9. Notice of Dissolution of Group

Not applicable.

Item 10. Certification

By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

Exhibits:

Exhibit I: Joint Filing Agreement, dated as of June 26, 2024, by and among Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander.

SIGNATURE

After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information with respect to it set forth in this statement is true, complete, and correct.

Dated: June 26, 2024

MILLENNIUM MANAGEMENT LLC

By: /s/Gil Raviv

Name: Gil Raviv

Title: Global General Counsel

MILLENNIUM GROUP MANAGEMENT LLC

By: /s/Gil Raviv

Name: Gil Raviv

Title: Global General Counsel

/s/ Israel A. Englander

Israel A. Englander

EXHIBIT I

JOINT FILING AGREEMENT

This will confirm the agreement by and among the undersigned that the Schedule 13G filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the Common Stock, par value \$0.001 per share, of Verve Therapeutics, Inc. will be filed on behalf of each of the persons and entities named below in accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

Dated: June 26, 2024

MILLENNIUM MANAGEMENT LLC

By: /s/Gil Raviv

Name: Gil Raviv

Title: Global General Counsel

MILLENNIUM GROUP MANAGEMENT LLC

By: /s/Gil Raviv

Name: Gil Raviv

Title: Global General Counsel

/s/ Israel A. Englander

Israel A. Englander